Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 3 Relative Benefit of DES Over BMS for Safety and Efficacy
Adjusted hazard ratios (solid squares) and 95% confidence intervals (horizontal lines) for safety and efficacy outcomes at 1-year comparing DES-treated versus BMS-treated (referent category) patients, stratified by diabetes treatment regimen. Variables adjusted for included age, vessel disease, history of congestive heart failure, hypertension, prior coronary intervention, peripheral vascular disease, history of hypercholesterolemia, number of significant lesions, renal disease, presence of total occlusion, tortuous lesion, unstable angina, acute myocardial infarction, cardiogenic shock, emergency procedure, urgent procedure, attempted an ostial lesion, attempted a class C lesion, attempted lesion receiving collaterals, attempted thrombus, and discharge medication (i.e., presence of at least 2 of the following: beta-blockers, calcium blocker, long-acting nitrates, angiotensin-converting enzyme inhibitors, statins, clopidogrel/ticlopidine). Abbreviations as in Figure 1.
|
